Since activating PI3K mutations that are oncogenic [11,12] are present in about 25% of breast tumors [7-9], and E545K is one of the most common PI3K mutations in breast cancer, it will be of uttermost importance to clarify the mutation status of breast cancer patients before aiming at treatments based on flotillin ablation. The gene discussed is PIK3CA; the disease is breast carcinoma.